Centre to provide 96,490 Covid vaccine doses to states, UTs in next 3 days

Implementation of the liberalised and accelerated phase-3 strategy of Covid-19 vaccination has started from May 1, 2021.

coronavirus, vaccine, vaccination, covid-19
Press Trust of India New Delhi
2 min read Last Updated : Jun 14 2021 | 7:12 PM IST

More than 1.40 crore COVID-19 vaccine doses are still available with the states and Union Territories to be administered and over 96,490 vaccine doses are in the pipeline and will be received by them within the next three days, the Union Health Ministry said on Monday.

Over 26.68 crore (26,68,36,620) vaccine doses have been provided to states and Union Territories so far through the Government of India and direct state procurement category.

Of this, the total consumption, including wastage, is 25,27,66,396 doses, the ministry said.

"More than 1.40 crore (1,40,70,224) Covid vaccine doses are still available with the states and UTs to be administered. Furthermore, over 96,490 vaccine doses are in the pipeline and will be received by them within the next three days," the ministry said.

As part of the nationwide vaccination drive, the Government of India has been supporting the states and UTs by providing them COVID-19 vaccines free of cost.

In addition, the government has also been facilitating direct procurement of vaccines by the states and UTs.

Vaccination is an integral pillar of the comprehensive strategy of the Government of India for containment and management of the pandemic, along with test, track, treat strategy and Covid-appropriate behaviour.

Implementation of the liberalised and accelerated phase-3 strategy of Covid-19 vaccination has started from May 1, 2021.

Under the strategy, in every month 50 per cent of the total Central Drugs Laboratory (CDL) cleared vaccine doses of any manufacturer would be procured by the Government of India. It would continue to make these doses available to the state governments totally free of cost as was being done earlier, the ministry said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 14 2021 | 7:08 PM IST

Next Story